![]()
Welcome to NCCRED News, May 2023 edition. The year is in full swing across NCCRED’s growing team and range of projects. In this edition of the NCCRED News:
Research spotlight NCCRED drives innovation and builds clinical research capacity through an internal program of clinical research as well as a grants and seed funding program, higher education scholarships program and research fellowships program. Check out our most recent research highlights: Strengthening first line telehealth The role of technology in Methamphetamine Treatment Lisdexamfetamine for Methamphetamine Withdrawal, safety and feasibility (the OLAM study) ![]() NCCRED grant funded research: Co-designing drug alerts for health and community workers for an emerging early warning system in Victoria, Australia Series 2023 Monday - 15 May 2023 - 12pm AEST Discontinuation of Opioid Treatment Programs with Dr Thomas Lu Check out our 2023 program
![]() ![]() The Prompt Response Network (PRN) is a national project bringing together existing and emerging early warning networks across the country regarding emerging drugs of concern and enabling a rapid response to reduce harm associated with them. Kept in the Know Three alerts were published in May:
The PRN will be launching The Know website soon, stay tuned for details about where you can find links to alerts released across Australia! Be a part of The Know Community The PRN has developed The Know Community, an online professional community platform, for PRN stakeholders from each jurisdiction to collaborate and share information on alerts and emerging drugs. If you are interested in joining the platform, it is via referral only. Email PRN@nccred.org with the following information, name, email, organisation and mention this newsletter. The PRN will create an account for you to activate. Join the PRN team! If you are interested in working on the PRN, NCCRED is actively recruiting for a PRN Lead and Post-Doctoral Fellow, Post-Doctoral Fellow (Emerging Drugs). The National Centre for Clinical Research on Emerging Drugs is made up of a consortium of the following four institutions |